Hologic to Showcase 3D Mammography and Other Recent Innovations in Healthcare at the 38th Arab Health Congress in Dubai
-- Hologic is focused on products that improve the lives of women all over the world
BEDFORD, Massachusetts, Jan. 28, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will feature 3D mammography (breast tomosynthesis) and other new innovations in healthcare at the 38th Arab Health Congress at the Dubai International Convention and Exhibition Centre, 28 January through 31 January, 2013. The Arab Health Congress is the leading educational healthcare conference series in the Middle East, annually attracting over 83,000 attendees from 142 countries.
"The Arab Health Congress is our opportunity to reach out to physicians, administrators, hospitals and laboratories serving the fast growing healthcare market in the Middle East," said David Harding, Hologic's Senior Vice President and General Manager, International. "The Middle East is an important market for Hologic. We are investing significant resources to support the strategic growth of our business base in this area. This conference is the ideal venue for us to show potential customers our extensive portfolio of healthcare products and solutions."
Hologic is expanding its presence in the region by opening a new office in Dubai Healthcare City. The office, currently planned to be open in the first quarter of 2013, should provide enhanced service for customers and improved sales and marketing support for Hologic's strategic distribution partners in the Middle East.
Hologic products featured at Arab Health include:
Breast Cancer Screening and Diagnosis
Hologic is the largest provider of 2D and 3D mammography (breast tomosynthesis) systems in the world. The Company offers a full line of flexible and robust systems designed to fit the needs of large and small hospitals, free standing imaging centers and mobile coaches.
Hologic's Selenia Dimensions 2D/3D mammography systems are installed in over 30 countries. More than a million women have been screened to date with the new technology. The system received CE marking in 2008 and is the only 3D system approved for sale in the U.S. A new C-View synthesized 2D image option available in countries recognizing the CE mark, is designed to provide workflow efficiencies and offer a lower dose alternative for patients.
Hologic's SecurView diagnostic workstation features viewing tools designed to provide efficient reading of digital mammography and tomosynthesis exams, as well as 2D and 3D computer-aided detection applications and breast density assessment software.
Breast Biopsy Solutions
Hologic's new 3D mammography biopsy option for use with the Affirm biopsy guidance system, is designed to allow the use of tomosynthesis to locate and accurately target regions of interest for biopsy, including lesions visible only in tomosynthesis images. Hologic's ATEC breast biopsy system is designed to conduct minimally invasive biopsy procedures under stereotactic, ultrasound, or MRI guidance.
Bone Density and Body Composition Assessment
Hologic's Discovery bone densitometry platform features a new Advanced Body Composition Assessment package designed to assist clinicians with the diagnosis and monitoring of obesity related metabolic diseases, athletic training regimens and sports injury rehabilitation programs.
Hologic's NovaSure endometrial ablation system is designed to offer a quick, simple procedure to treat heavy menstrual bleeding. This minimally invasive procedure can be performed in a physician's office, making it the procedure of choice for millions of women. Hologic's MyoSure tissue removal device is designed to provide fast, incision-less removal of fibroids and polyps.
Cervical Cancer Screening
Hologic's ThinPrep Pap Test and ThinPrep Imaging Systems are acknowledged worldwide as the gold standard for cervical cancer detection. The ThinPrep Pap Test provides improved disease detection compared to the conventional Pap smear and for further testing for HPV, Chlamydia, and Gonorrhea straight from the vial. The ThinPrep Imaging system provides increased sensitivity and specificity over manually reviewed ThinPrep Pap Test slides.
Hologic's fetal fibronectin test (fFn) aids in assessing preterm birth risk and may provide valuable information to support management and treatment options for the mother.
Molecular Diagnostic Solutions
Hologic's PANTHER System is a world class automation solution for small, medium and large laboratories. The APTIMA Trichomoniasis vaginalis Assay on the PANTHER System offers an amplified nucleic acid test to detect Trichomoniasis vaginalis, a common curable sexually transmitted infection. The assay may be used to test clinician-collected endocervical or vaginal swabs, and specimens collected in Hologic's ThinPrep vial from symptomatic or asymptomatic women.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Hologic, Advanced Body Composition, Affirm, APTIMA, ATEC, C-View, Dimensions, Discovery, MyoSure, NovaSure, PANTHER, Selenia, and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.
SOURCE Hologic, Inc.
Mer från detta företag
Hologic Introduces New Tomcat Pre-analytical Sample Processing Instrument in Europe
17 Sep, 2014, 09:00 CET
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till email@example.com eller ring oss på +46 (0)8 1200 1300
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300